Encouraging results of researchers COVID-19 potential treatments to look into are called “revolutionary development”, but recent history shows that taking these promising results with a grain of salt is worth welcoming. Investigators on the British patent office shooting in a working basis today announced that dexamethasone, low cost and widely available steroid that reduces inflammation, improving the ability of the patient to survive heavy COVID-19 During the study, more than 2,100 COVID-19 patients were treated for 10 days with dexamethasone. In patients receiving mechanical ventilation, which dexamethasone was 35% were less likely to die than patients treated with fans who do not get treatment. In patients with less invasive forms of assistance in breathing, dexamethasone reduced the risk of death by 20%, while patients who have not ventilatory support were not needed improvements saw take the steroid. These results are promising, and it makes sense that an anti-inflammatory drug would be effective against a disease that is particularly harmful when there is excess body inflammation of the spores. But there is one big disadvantage: only a summary of the data allowed the researchers, rather than a complete document, peer-reviewed. (The researchers said they will soon release the full results in a statement.) It ”s understandable that these researchers would like to receive the news as soon as possible, given the possibility that dexamethasone was based on the result immediately to save the life. But some health experts warn the public to interpret the results with caution, especially in light of the recent scandal in which two major medical journals, The Lancet and the New England Journal of Medicine, had to withdraw high-profile studies on possible treatments COVID- 19 for suspicious items. “It will be good news if dexamethasone, a steroid cheap, really cut deaths from 03/01 does in mechanically ventilated patients with COVID-19, but after all recoveries and back, is not acceptable results of the study in a communique Press tout without releasing the paper, “influential surgeon and author Dr. Atul Gawande wrote today morning on Twitter. The antimalarial drug hydroxychloroquine serves as a cautionary tale. A small French study from March has sparked a flurry of excitement (and as president Donald Trump glowing praise) on hydroxychloroquine potential to treat COVID-19 But as robust studies come out, results suggest began the medication, it is at best ineffective potentially harmful at worst. Finally, the growing number of studies of the US Food and Drug Administration for approval of emergency led revoked medication. The hope, of course, is that something happens with dexamethasone. If the drug really and initial results suggest working towards it might be the way in which it is treated heavy COVID-19 Revolutionizing. But the rapid evolution COVID-19 pandemic, scientists stimulated to produce a surprising amount of work in record time, even the acceleration of the disadvantages of traditionally slow and steady scientific review process is exposed. Mistakes happen, and conclusions change, especially when the whole world is looking forward to answers.
Low cost steroids shows promise for the treatment COVID-19 But take this news with a grain of salt
